COVID-19 therapy: better in combination than alone

How a well-known drug can become a game changer - A joint press release by Charité, the MDC and FU Berlin. There is a steadily growing arsenal of drugs for COVID-19. Researchers from Charité - Universitätsmedizin Berlin, the Max Delbrück Center for Molecular Medicine (MDC) and Freie Universität (FU) Berlin have studied the mechanisms of action of antiviral and anti-inflammatory drugs. Their findings, which have been published in Molecular Therapy*, show that treatment effects were best with combination therapy involving both types of drugs. This treatment regimen also had the additional benefit of increasing the time window available for antibody therapy. SARS-CoV-2 infections continue to result in hospitalizations. According to estimates by the Robert Koch Institute, the current COVID-19 hospitalization rate is approximately six to seven per 100,000 of the resident population.